AIM ImmunoTech Inc. (AIM) stock

AIMNYSEBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 2/30

$0.15+0.00 (+0.13%)

Close on Nov 12, 2026Market cap $4.52MP/E –Yield –

AIM ImmunoTech ebitda

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.

Change is against the same quarter a year earlier.

Period	Period end	Value	Change
Q3 FY2026	Sep 30, 2026	-$2.68M	–
Q3 FY2025	Sep 30, 2025	-$2.27M	–

Parsed from the XBRL in AIM ImmunoTech's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-100 reverse split on Jun 12, 2025
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is AIM.

Advertisement
300 × 250

See a number that looks wrong?